As endocrine resistance in ER-positive breast cancer is likely to be attributable to the abnormal regulation of ER network, the expression pattern changes of these genes were explored in tamoxifen- and fulvestrant-resistant breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.